about
Regulation of myeloid leukaemia by the cell-fate determinant MusashiImpaired DNA replication within progenitor cell pools promotes leukemogenesis.New Developments in Chronic Myeloid Leukemia: Implications for TherapyThe non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phaseManagement of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentTransformation of Canine Lymphoma/Leukemia to More Aggressive Diseases: Anecdotes or Reality?Functions of heterogeneous nuclear ribonucleoproteins in stem cell potency and differentiationRole of the transcription factor Bcl11b in development and lymphomagenesisEffect of cellular quiescence on the success of targeted CML therapyCombination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemiaOptimizing combination therapies with existing and future CML drugsIcaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsMisfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.Requirement of c-Myb for p210(BCR/ABL)-dependent transformation of hematopoietic progenitors and leukemogenesisExosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemiaA phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasBCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNKEffective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical ApproachDrug resistance in cancer: principles of emergence and prevention.Methylation status of DDIT3 gene in chronic myeloid leukemiap53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.Chronic myeloid leukemia: mechanisms of blastic transformationMechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignanciesDestabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)Cancer stem cells: a stride towards cancer cure?The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.Metabolism considerations for kinase inhibitors in cancer treatmentmiR-153 sensitized the K562 cells to As2O3-induced apoptosis.The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinibCancer stem cell plasticity and tumor hierarchy.Gene expression changes associated with progression and response in chronic myeloid leukemia.Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.
P2860
Q24634359-9E914CD3-4722-4E37-AC6E-6BF66BE36AE5Q24816866-43B7E24D-AE3B-47C2-ACFD-E193AEFFECDBQ26745669-3BD39B16-97E8-4493-974B-6399678E5CA9Q26749343-127A691E-D993-4532-9AFC-37BACC502A80Q26766299-0CC50741-64BE-4945-9280-7D96D02FB6EFQ26776071-AFCEFB47-2059-4C79-B562-1AAF33A3BB50Q26849397-FE02D4C1-95C6-4D18-B185-1329DD317E28Q27014084-7FE53794-3A05-4A1A-A918-5CB79630B413Q28469312-D78C5A49-3407-401B-9E27-EDADB952697DQ28474737-82C2A325-C907-470B-8F5F-EAA36BD1A3F6Q28475255-EFE7E0F4-2DE1-4237-8632-FEE544B8212DQ28741022-D9A76A7F-1CFE-42D1-ABE6-021B1A909395Q30374671-646AC4A2-905F-49BB-BB0F-56B4168D6EA2Q30439716-A9B6D4F0-E24C-4D08-ABC1-808A32C826B8Q30537455-87C016E2-EEEC-4BFE-A768-12E9378C0C55Q30608477-74C2B1BD-A200-48D4-BF6F-016283EED6B2Q33411250-A8A548AB-DA4B-495C-842C-14341AD88BECQ33796384-0E3AE4E2-48BD-44FC-BBE6-2F300B71C2A8Q33810952-D2F03DFA-9831-449A-90F0-B61B5C3D0006Q33866597-9B42E3BA-BD84-4B69-83E7-4E8D724BFBCCQ33888064-F7D910EB-D1F1-4524-ACF9-43EC1F6EE3D9Q33892278-C687C954-1612-4643-B4AD-841031C7CED3Q33933648-72F769D0-C1E3-4A08-907A-1A22891E0369Q33953631-2623C08D-0277-41AE-89B3-6CC1DDC649F9Q33968037-3D20E162-FDEA-4DF1-AC7C-3191C3087CF2Q34016866-C8BC2E11-D2DF-4AD5-A15E-2248B3AC4B86Q34081636-CA3C527F-F2DB-4939-806A-1A58906CB28EQ34082540-24E0CE5F-64FE-45E2-979C-B8FB973CABA8Q34086837-8327845B-5D2A-4BDF-A176-D00841060FBDQ34099472-697FB99E-A6DE-47E3-B343-63EF0253822CQ34134390-139ABF26-496C-476F-B706-14D3046335BBQ34160845-63F6FA1E-5528-4E59-901B-8B4D9F64D573Q34167708-60B5D257-20C2-43F7-9659-C869E0C1D00CQ34204486-D17DBB77-1874-418F-8D70-5A0133D51608Q34272962-7900F0FE-7842-4973-9F12-3C6B83CE6759Q34369606-845164C1-AA43-494C-B0C4-92B46FAF5B07Q34459650-2BF548B2-6DC9-475D-A41D-E8381A926FBDQ34479561-2AB79EC3-B6FF-4232-B323-1144399B436DQ34532048-B0AFEC6E-3AB1-48B9-B52B-C8E17CF0F3C1Q35102301-F8BCE8CF-843C-4121-BA85-0429536568DF
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The biology of CML blast crisis.
@ast
The biology of CML blast crisis.
@en
type
label
The biology of CML blast crisis.
@ast
The biology of CML blast crisis.
@en
prefLabel
The biology of CML blast crisis.
@ast
The biology of CML blast crisis.
@en
P1433
P1476
The biology of CML blast crisis.
@en
P2093
Bruno Calabretta
Danilo Perrotti
P304
P356
10.1182/BLOOD-2003-12-4111
P407
P577
2004-02-24T00:00:00Z